A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will provide optional continuation of double-blind treatment with CellCept
or placebo, in patients with myasthenia gravis who have achieved good symptom control in
study WX17798. Patients who have completed 36 weeks of treatment in study WX17798, with
stable prednisone dosing for the last 4 weeks, can continue on blinded treatment with
CellCept (1g bid) or placebo until the database for WX17798 is locked and unblinded. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.